Talking points for physicians, patients and caregivers considering Aduhelm® infusion and the accelerated pathway for its approval by the FDA
Guardado en:
Autores principales: | Sam Gandy, David S. Knopman, Mary Sano |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
BMC
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/f92c16d8aa1a4a8380db476dc21f17d2 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Topical Insights Into the Post-Approval Controversies of Aducanumab
por: Dhiraj Kumar, et al.
Publicado: (2021) -
Is Aducanumab for LMICs? Promises and Challenges
por: Illangage P. C. Gunawardena, et al.
Publicado: (2021) -
Amyloid
Publicado: (1994) -
Can an FDA-Approved Alzheimer’s Drug Be Repurposed for Alleviating Neuronal Symptoms of Zika Virus?
por: Devika Sirohi, et al.
Publicado: (2017) -
Identification of new EphA4 inhibitors by virtual screening of FDA-approved drugs
por: Shuo Gu, et al.
Publicado: (2018)